groninger At CPHI 2025: Efficient, Flexible, Scalable

From October 28 to 30, 2025, the international pharmaceutical industry will gather in Frankfurt for CPHI – one of the most important global events in the sector. Among the exhibitors: groninger, a specialist in filling and closing systems, showcasing innovative machine solutions for processing pharmaceutical liquids in small and medium batch sizes. On the 130-square-meter exhibition space, visitors will experience firsthand how groninger responds to current industry demands with flexible and scalable machine concepts.

Crailsheim - Live at Booth #A06 in Hall 9, visitors will experience how groninger responds to current industry demands with flexible and scalable system concepts. Direct interaction with on-site experts offers valuable insights into practical applications and the future of pharmaceutical production.

“CPHI is one of the key platforms for us to present our latest developments to an international professional audience,” agree Dirk Schuster, Vice President Sales Pharma, and Otto Helmle, Vice President Sales Consumer Healthcare at groninger.

This year’s focus is on flexfill and labworx – two innovative machine solutions for the sterile processing of pharmaceutical liquids in small and medium batch sizes. “We’re highlighting a segment that is gaining importance and where we can apply our technological strengths in a targeted way.”

The growing relevance of smaller batch sizes is closely linked to the transformation in pharmaceutical research and production – particularly driven by the rise of personalized medicine. This approach aims to tailor therapies to the genetic, biological, and molecular characteristics of individual patients. Instead of standardized mass-market drugs, customized active ingredients are coming to the forefront, promising greater efficacy and fewer side effects.

Personalized therapies are especially relevant in oncology, immunotherapy, cell and gene therapy, and rare diseases. Developing such medicines requires highly flexible production processes, as batch sizes are often very small and product requirements can vary significantly – directly impacting processing needs.

At the same time, regulatory demands for safety, traceability, and quality continue to rise across the industry.

“This evolution presents new challenges for the pharmaceutical sector,” explains Dirk Schuster. groninger’s machine concepts are designed to meet these demands, enabling precise, safe, and scalable processing – both in sterile and non-sterile environments.

Scalability as a key success factor

A standout feature of the systems showcased at CPHI is their shared technological foundation. Both flexfill and labworx rely on the same proven components and control concepts used in groninger’s high-speed systems. This technological consistency enables seamless technology transfer – from R&D and clinical trials to commercial production. “We place great emphasis on a unified technological base in our machine solutions, because scalability is a decisive success factor for our customers,” says Dirk Schuster. “Those starting in the lab today must be able to scale up tomorrow – processing larger volumes under identical conditions, without compromising quality or requiring complex redevelopment.”

“This trend is also clearly visible in non-sterile environments,” adds Otto Helmle. Product life cycles are shortening, pharmaceutical portfolios are diversifying, and markets demand rapid responses to changing trends. “Our customers face the challenge of switching between formats and formulations within ever tighter timeframes – without sacrificing quality, safety, or system availability.”

groninger’s philosophy of technological continuity makes the company a reliable partner for businesses that need to respond flexibly to market demands while maintaining the highest quality standards.

From custom engineering to platform solutions

“This is one of the core principles we apply to our systems today,” says Jens Groninger, Managing Partner of the groninger Group. This mindset now shapes the company’s entire machine strategy and reflects the transformation groninger has undergone in recent years: from a traditional custom machine builder to a provider of modular platform solutions and turnkey partner. Upon request, groninger takes full project responsibility – from layout planning and component selection to interface management, installation, qualification, and commissioning.

For customers, this means: one central contact, fewer interfaces, streamlined processes, and shorter project timelines – all from a single source. “The close integration of all project phases ensures greater efficiency and reliability – a decisive advantage, especially given the complexity of today’s industry requirements,” says Dirk Schuster.

“We are now able to offer both worlds,” confirms Jens Groninger. Customers can choose between modular platform solutions with short lead times and high scalability based on proven standards, or tailor-made systems customized to their specific needs – all in the trusted groninger quality.

“CPHI gives us the opportunity to discuss this strategic evolution directly with our customers and partners – in person, with concrete examples, and with a view to tomorrow’s requirements,” agree Jens Groninger, Dirk Schuster, and Otto Helmle. “We look forward to engaging in meaningful conversations.”

About groninger

groninger is one of the leading international manufacturers of filling and closing machines for the pharmaceutical, consumer healthcare and cosmetics industries. The slogan “We fill Visions with Life” sums up what groninger stands for – excellent know-how, innovative solutions and cooperative partnership in design of customized machines. Since the founding of the company in 1980 by Horst Groninger, groninger has developed into a hidden champion and innovation leader in the industry. Today, the second generation of the family business employs over 1,600 people in Crailsheim, Schnelldorf and Charlotte (USA). The company’s headquarters are in Crailsheim, Baden-Württemberg.